These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 37450478)

  • 1. Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    Bradshaw D; Abramowicz I; Bremner S; Verma S; Gilleece Y; Kirk S; Nelson M; Housman R; Miras H; Orkin C; Fox A; Curnock M; Jennings L; Gompels M; Clarke E; Robinson R; Lambert P; Chadwick D; Perry N
    PLoS One; 2023; 18(7):e0288598. PubMed ID: 37450478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
    Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
    Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Chronotype and Mediterranean Diet on the Risk of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Rosso C; Guariglia M; Armandi A; Nicolosi A; Caviglia GP; Bugianesi E
    Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials.
    Cao C; Shi M; Wang X; Yao Y; Zeng R
    Front Nutr; 2023; 10():1155306. PubMed ID: 37457967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diets with Higher Anti-inflammatory Potential Associated with Lower Risk of Development of Nonalcoholic Fatty Liver Disease and Early-Stage of Fibrosis Among US Adults.
    Li R; Li M; Bidulescu A; Fly AD; Luo J
    Dig Dis Sci; 2023 Oct; 68(10):4009-4021. PubMed ID: 37535123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the Bile Acid Transporter Genes
    Kreimeyer H; Vogt K; Götze T; Best J; Götze O; Weigt J; Kahraman A; Özçürümez M; Kälsch J; Syn WK; Sydor S; Canbay A; Manka P
    J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
    Noureddin M; Truong E; Mayo R; Martínez-Arranz I; Mincholé I; Banales JM; Arrese M; Cusi K; Arias-Loste MT; Bruha R; Romero-Gómez M; Iruzubieta P; Aller R; Ampuero J; Calleja JL; Ibañez-Samaniego L; Aspichueta P; Martín-Duce A; Kushner T; Ortiz P; Harrison SA; Anstee QM; Crespo J; Mato JM; Sanyal AJ
    Hepatology; 2024 Jan; 79(1):135-148. PubMed ID: 37505221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD.
    De A; Mehta M; Singh P; Bhagat N; Mitra S; Das A; Duseja A
    Int J Obes (Lond); 2023 Oct; 47(10):986-992. PubMed ID: 37474570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Shenlian formula on microbiota and inflammatory cytokines in adults with type 2 diabetes: a double-blind randomized clinical trial.
    Li J; Qiang FU; Shidong W; Jinxi Z; Yu C; Jiayue LI; Yonghua X; Weijun H; Ruixi S; Yao X; Aijia S; Junheng W; Jiangteng L; Xiaozhe FU; Yuanyuan LI; Yu Z; Taiqi X
    J Tradit Chin Med; 2023 Aug; 43(4):760-769. PubMed ID: 37454261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Stratification of Advanced Fibrosis in HIV Patients With Hepatic Steatosis Using the NAFLD Fibrosis and BARD Scores.
    Yendewa GA; Khazan A; Jacobson JM
    medRxiv; 2023 Jul; ():. PubMed ID: 37461460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of chronic liver diseases on the course and outcome of COVID-19.
    Mitrovic N; Sabanovic M; Vujovic A; Jovanovic J; Nikolic N; Jug M; Todorovic N; Filipovic A; Milosevic I
    PLoS One; 2023; 18(7):e0288350. PubMed ID: 37450541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Thyroid Hormones and Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Obese Individuals Undergoing Bariatric Surgery.
    Ashraf Ganjooei N; Jamialahmadi T; Nematy M; Shah NZ; Jangjoo S; Emami N; Jangjoo A; Faridnia R; Alidadi M; Sathyapalan T; Sahebkar A
    Middle East J Dig Dis; 2022 Oct; 14(4):410-421. PubMed ID: 37547501
    [No Abstract]   [Full Text] [Related]  

  • 13. Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people with HIV in France.
    Palich R; Hentzien M; Hocqueloux L; Duvivier C; Allavena C; Huleux T; Makinson A; Rey D; Delobel P; Cuzin L;
    AIDS; 2023 Oct; 37(12):1891-1896. PubMed ID: 37451430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine).
    Singh B; Guliani A; Hanumanthu V; Narang T; Dogra S; Handa S; Sharma A
    Indian J Sex Transm Dis AIDS; 2023; 44(1):6-10. PubMed ID: 37457534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the efficacy and safety of acotiamide in patients with esophagogastric junction outflow obstruction: study protocol for an investigator-initiated, multi-center, randomized, double-blind, placebo-controlled phase II trial.
    Esaki M; Ihara E; Manabe N; Kawami N; Iwakiri K; Akiyama J; Kuribayashi S; Uraoka T; Ogino H; Chinen T; Misumi A; Watanabe H; Suzuki M; Kishimoto J; Ogawa Y
    Trials; 2023 Jul; 24(1):459. PubMed ID: 37464279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective double-blinded randomized study on drug-eluting stent implantation into nitrate-induced maximally dilated vessels in patients with coronary artery disease.
    Yoon GS; Choi SH; Kwon SW; Park SD; Woo SI
    Trials; 2023 Jul; 24(1):460. PubMed ID: 37464355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Accuracy of Vibration Controlled Transient Elastography as Non-invasive Assessment of Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease.
    Salehi H; Salehi AM; Ghamarchehreh ME; Khanlarzadeh E; Sohrabi MR
    Middle East J Dig Dis; 2023 Jan; 15(1):26-31. PubMed ID: 37547160
    [No Abstract]   [Full Text] [Related]  

  • 19. The chemokine receptor type 5 inhibitor maraviroc alleviates sepsis-associated liver injury by regulating MAPK/NF-κB signaling.
    Shao J; Wang T; Tang C; Yu J; Chen Y; Guo X; Wang H; Zhou L; Zhang G; Li Y; Yu H; Zheng R
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Oct; ():. PubMed ID: 39352530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty Liver Disease: Enter the Metabolic Era.
    Wegermann K; Moylan C; Naggie S
    Curr HIV/AIDS Rep; 2023 Dec; 20(6):405-418. PubMed ID: 37882965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.